EUVIMEDEUVIMED entdecken
Crossref

KRAS mutations disrupt interactions between CD8+ T cells and antigen-presenting cells in the tumor microenvironment of biliary tract cancer

Fumihiro Terasaki iD, Shogo Kumagai, Akito Fukuda, Yosuke Tanaka, Takuma Irie, Sachiko Ito, Mihoko Yamada, Shunsuke Onoe, Takashi Mizuno, Toshio Kokuryo, Shohei Koyama, Kennosuke Karube und 2 weitere

International Immunology · 2026

DOI: 10.1093/intimm/dxaf065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunology, 2026. Verfasst von Fumihiro Terasaki und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan. Hauptthemen laut MEDLINE: Tumor Microenvironment, CD8-Positive T-Lymphocytes, Proto-Oncogene Proteins p21(ras), Biliary Tract Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Grants-in-Aid for Scientific Research, JSPS, Early-Career Scientists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biliary tract cancer (BTC) exhibits a poor prognosis and limited responses to current therapeutic strategies. While surgical resection followed by adjuvant S-1 therapy is the standard curative treatment for BTC, long-term postoperative remission is hardly achieved. Therefore, more effective perioperative strategies are urgently needed. Here, we show that an immune-cold tumor microenvironment (TME) in KRAS-mutated BTC correlated with resistance to postoperative adjuvant S-1 therapy. Surgically resected tumor specimens were collected from 31 BTC patients who received adjuvant S-1 therapy after surgery and were subjected to integrated immunogenomic analysis, including multiplexed immunohistochemistry staining and whole-exome sequencing. The analysis revealed a strong correlation between limited CD8⁺ T cell and antigen-presenting cell (APC) infiltration into the TME and KRAS mutations in BTC. In addition, the distances between tumor cells and APCs, as well as between APCs and CD8⁺ T cells, were significantly greater in the TME of KRAS-mutated BTC than in that of KRAS wild-type BTC. These findings indicate that interactions between effector T cells and APCs were impaired in the TME of KRAS-mutated BTC, thereby disrupting antitumor immune responses. Furthermore, wild-type KRAS and abundant CD8⁺ T cells and APCs correlated with a favorable prognosis following adjuvant S-1 therapy for BTC. Altogether, we propose a novel immunogenomic-based biomarker for optimizing perioperative chemotherapy for BTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentCD8-Positive T-LymphocytesProto-Oncogene Proteins p21(ras)Biliary Tract NeoplasmsAntigen-Presenting CellsHumansMutationFemaleMaleMiddle AgedAgedAdult

Stichwörter der Autor:innen

adjuvant therapycholangiocarcinomadriver gene mutationsgallbladder cancertumor immune microenvironment

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
  • Division of Cancer Immunology, Research Institute, National Cancer Center, Tokyo 104-0045, Japan.
  • Division of Cancer Immunology, Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Chiba 277-8577, Japan.
  • Division of Cellular Signaling, Research Institute, National Cancer Center, Tokyo 104-0045, Japan.
  • Department of Immunogenomic Medicine, Research Institute, National Cancer Center, Tokyo 104-0045, Japan.
  • Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.

ORCID-Profile: Fumihiro Terasaki, Hiroyoshi Nishikawa

Förderung

  • Grants-in-Aid for Scientific Research
  • JSPS
  • Early-Career Scientists
  • Wellcome Trust
  • PAGS
  • Japan Agency for Medical Research and Development
  • Moonshot Research and Development Program
  • Next-generation Drug Discovery

Zitieren

APA

Terasaki, F., Kumagai, S., Fukuda, A., Tanaka, Y., Irie, T., Ito, S., Yamada, M., Onoe, S., Mizuno, T., Kokuryo, T., Koyama, S., Karube, K., Nishikawa, H., & Ebata, T. (2026). KRAS mutations disrupt interactions between CD8+ T cells and antigen-presenting cells in the tumor microenvironment of biliary tract cancer. International Immunology. https://doi.org/10.1093/intimm/dxaf065

Vancouver

Terasaki F, Kumagai S, Fukuda A, Tanaka Y, Irie T, Ito S, et al. KRAS mutations disrupt interactions between CD8+ T cells and antigen-presenting cells in the tumor microenvironment of biliary tract cancer. International Immunology. 2026. doi:10.1093/intimm/dxaf065

BibTeX
@article{Terasaki2026,
  author = {Terasaki, Fumihiro and Kumagai, Shogo and Fukuda, Akito and Tanaka, Yosuke and Irie, Takuma and Ito, Sachiko and Yamada, Mihoko and Onoe, Shunsuke and Mizuno, Takashi and Kokuryo, Toshio and Koyama, Shohei and Karube, Kennosuke and Nishikawa, Hiroyoshi and Ebata, Tomoki},
  title = {KRAS mutations disrupt interactions between CD8+ T cells and antigen-presenting cells in the tumor microenvironment of biliary tract cancer},
  journal = {International Immunology},
  year = {2026},
  doi = {10.1093/intimm/dxaf065}
}
Kostenlos starten →